GLPwatch
Papers (9189)
Page 119 of 154, ranked by citation count.
- Semaglutide attenuates lipotoxicity-induced cardiac injury by inhibiting Slc27a2 expression.
- Physiology of the Weight Loss Plateau after Calorie Restriction, GLP-1 Receptor Agonism, and Bariatric Surgery.
- Exendin-4 effects on islet volume and number in the mouse pancreas.
- A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure.
- Efficacy of liraglutide as a follow-up therapy after resolution of glucotoxicity with intensive insulin therapy.
- [Semaglutide, once weekly GLP-1 receptor agonist (Ozempic®)].
- [Liraglutide and glimepiride on glycaemic control in type 2 diabetes in the Mexican cohort (LEAD 3)].
- Comparative cardiovascular and renal outcomes of Liraglutide versus Dulaglutide in Asian type 2 diabetes patients.
- Semaglutide treatment in hypothalamic obesity: Two-Year outcomes on body composition, appetite, and quality of life.
- Tirzepatide for the treatment of adults living with concurrent type 1 diabetes and overweight or obesity (TZP-T1D): a double-blind, placebo-matched randomised controlled trial protocol.
- GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study.
- Building the Glucagon-Like Peptide-1 Receptor Brick by Brick: Revisiting a 1993 Diabetes Classic by Thorens et al.
- The prostaglandin E<sub>2</sub> EP3 receptor has disparate effects on islet insulin secretion and content in β-cells in a high-fat diet-induced mouse model of obesity.
- Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial.
- The effects of glucagon-like peptide-1 receptor agonists (GLP1-RAs) on alcohol-related outcomes: a systematic review and meta-analysis.
- Case Report: A case of occult insulinoma localized by [<sup>18</sup>F] FB (ePEG12)12-exendin-4 positron emission tomography with negative findings of selective arterial calcium stimulation test.
- In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
- Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats.
- Protective roles of liraglutide against brain injury of streptozotocin induced diabetic rats.
- 'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.
- The effect of GLP-1 receptor agonists on cognition in nondiabetic patients with mild cognitive impairment or alzheimer's disease: a meta-analysis of randomized controlled trials.
- Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare.
- Meta-analysis of seven heterogeneous studies on liraglutide add-on therapy in patients with type 2 diabetes mellitus treated with insulin.
- Generalizability of results from the recent FDA-guided cardiovascular outcomes trials to a representative population with Type 2 Diabetes attending primary care clinics.
- GLP-1RA Reduces Supraspinatus Fatty Infiltration and Promotes Functional Recovery in a Rat Model of Rotator Cuff Repair.
- Lithium Toxicity and Altered Clearance Following Initiation of Semaglutide in Patients With Bipolar Disorder: A Case Series and Literature Review.
- Semaglutide and risk of suicidal ideations.
- The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the LIRAFLAME randomized, double-blinded, placebo-controlled trial.
- Exendin-4 intervention attenuates atherosclerosis severity by modulating myeloid-derived suppressor cells and inflammatory cytokines in ApoE<sup>-/-</sup> mice.
- GLP-1 receptor agonists and preconception planning: bridging the gap between obesity treatment and reproductive safety, a narrative review.
- Diabetes Mellitus and Cardiovascular Disease: An Evidence-Based Review of Provincial Formulary Coverage.
- Exenatide and Metformin Improve Serum Indices and Intestinal Flora in patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease.
- Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes.
- GLP1R agonists: primary cardiovascular prevention and oral administration.
- Efficacy and safety of exenatide once weekly: an overview of the DURATION trials.
- Lixisenatide in early parkinson's disease: efficacy, safety, and future directions: a correspondence.
- Use of liraglutide after bariatric surgery: a 36-month follow-up in a real-world setting in Chile.
- Semaglutide and weight loss - A concern for diabetics and pharmaceuticals.
- Utilization of antiobesity medications within the Military Health System.
- [Contribution of metabolic sensors on feeding behaviour and the control of body weight].
- Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial.
- Semaglutide reduces cardiovascular events in type 2 diabetes: a systematic review and meta-analysis highlighting enhanced benefits in chronic kidney disease.
- Therapeutic Function of Liraglutide for Mitigation of Blast-Induced Hearing Damage: An Initial Investigation in Animal Model of Chinchilla.
- Reduction of Hepatic Fat Content by Dulaglutide for the Treatment of Diabetes Mellitus: A Two-Centre Open, Single-Arm Trial.
- Exenatide in type 2 diabetes.
- Therapy: Liraglutide - preventing or postponing T2DM diagnosis?
- Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway.
- Inotropic effects of retatrutide in isolated human atrial preparations.
- Semaglutide-induced Wernicke encephalopathy: a comprehensive analysis.
- Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
- Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD).
- Structural stability-chromatographic retention relationship on exenatide diastereomer separation.
- Engineered microenvironments and pancreatic islet-on-chips for screening sugar substitute and antidiabetic compounds.
- Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts.
- The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.
- Peptide-Coated Polycaprolactone-Benzalkonium Chloride Nanocapsules for Targeted Drug Delivery to the Pancreatic β-Cell.
- Semaglutide reduces the absolute risk of major cardiovascular events by 1.5.
- Tirzepatide Helps Adults With Obesity Without Diabetes Lose 15% to 21% of Their Body Weight Over 72 Weeks.
- Putting More Weight on Obesity Trials in Heart Failure.
- Effects of six months treatment with liraglutide among patients with psoriasis and obesity, beyond metabolic control?